Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
Portfolio Pulse from Vandana Singh
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to Buy from Sell, with a price target of $19, up from $8. The upgrade comes after strong interim Phase 2 data from its Ocaliva + bezafibrate combination. The analyst also notes that Intercept may continue to grow and significantly expand the PBC market along with CymaBay Therapeutics Inc's (NASDAQ:CBAY), GSK Plc's (NYSE:GSK), and, to a lesser extent, Ipsen/GENFIT.
July 13, 2023 | 6:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics is expected to grow and significantly expand the PBC market along with Intercept Pharmaceuticals, according to HC Wainwright.
The positive outlook for CymaBay Therapeutics in the PBC market, as noted by HC Wainwright, could potentially drive the stock price up in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
GENFIT is expected to grow and expand the PBC market, but to a lesser extent compared to Intercept Pharmaceuticals, CymaBay Therapeutics, and GSK Plc, according to HC Wainwright.
The positive, but comparatively lesser, outlook for GENFIT in the PBC market, as noted by HC Wainwright, could potentially drive the stock price up in the short term, but not as much as the others.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
GSK Plc is expected to grow and significantly expand the PBC market along with Intercept Pharmaceuticals, according to HC Wainwright.
The positive outlook for GSK Plc in the PBC market, as noted by HC Wainwright, could potentially drive the stock price up in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Intercept Pharmaceuticals has been upgraded to Buy from Sell by HC Wainwright, with a new price target of $19, up from $8. This is due to strong interim Phase 2 data from its Ocaliva + bezafibrate combination.
The upgrade by HC Wainwright is a positive signal for Intercept Pharmaceuticals. The strong interim Phase 2 data from its Ocaliva + bezafibrate combination indicates potential for future growth and profitability, which could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100